



*Memorial Medical
Center*

A Sutter Health Affiliate

With You. For Life.

Cancer Services

Memorial Medical Center
1700 Coffee Road
Modesto, CA 95355
(209) 572-7237
(209) 526-5280 Fax

Clinical Trials – 2010

Brain:

N0574

Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in Patient with One to Three Cerebral Metastases.

RTOG

0825

Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma.

Breast:

S0221

Phase III Trial of Continuous Schedule AC + G vs. Every 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High Risk Node-Negative Breast Cancer.

PACCT-1

Program for the Assessment of Clinical Cancer Tests (also known as the TAILORx Trial: **T**rial **A**ssigning **I**ndividualized **O**ptions for **T**reatment).

CALGB

40101

A Phase III Randomized Study Cyclophosphamide and Doxorubicin (CA x 4 cycles) versus Paclitaxel (4 cycles) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes.

CALGB

70301

Quality of Life, Employment and Informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Breast Cancer with 0-3 Positive Axillary Lymph Nodes (Quality of Life study to 40101).

CALGB

40503

Endocrine Therapy in Combination with anti-VEGF Therapy: A Randomized, Double -Blind, Placebo-Controlled Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab For Women with Hormone Receptor-Positive Advanced Breast Cancer

Gastrointestinal:

E5202

A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers.

RTOG

0436

A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Who Are Treated Without Surgery.

Genitourinary:

- E2805** A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma.
- E3805** CHARTED (ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease) in Prostate Cancer.
- RTOG 0534** A Phase III Trial Of Short Term Androgen Deprivation With Pelvic Lymph Node Or Prostate Bed Only Radiotherapy (SPPORT) In Prostate Cancer Patients With A Rising PSA After Radical Prostatectomy.

Head & Neck:

- E1305** A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab In Patients with Recurrent Or Metastatic Head and Neck Cancer

Thorax:

- E1505** A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients with Completely Resected Stage 1B (>4cm)-IIIA Non-Small Cell Lung Cancer (NSCLC).
- RTOG 0617** A Randomized Phase III Comparison of Standard-Dose (60 Gy) Versus High-Dose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab in Patients With Stage IIIA/IIIB Non-Small Cell Lung Cancer.
- CALGB 30610** Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide.

**For any additional information regarding the above Clinical Trials,
contact Cathy Anthony, RN at (209) 526-4500, ext. 6015,
Elise Fredeking, RN at 526-4500, ext. 6192 or Denise Galbawy, RN at 572-7116.**